Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
Find the Advantages of Innovative Leisure activities: Supporting Creative mind and Self-Articulation- The Magnificence of Extraordinariness: Presenting Valuable Adornments and Gemstones
- Watch comet C/2026 A1 plunge toward the sun online this week
- Winter storms blanket the East, while the U.S. West is wondering: Where’s the snow?
- Vote in favor of the Web-based Work out schedule to Keep You Fit and Sound
- Polish law aimed at lowering petrol prices takes effect
- Dutch police probe a small blast outside a pro-Israel Christian center
- The most effective method to Guarantee Simple Availability in Seniors' SUVs
- 'People We Meet on Vacation' is the 1st of many Emily Henry adaptations: What other books turned movies to look forward to
